Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 13

Factors associated with appropriate inhaler use in patients with COPD – lessons from the REAL survey [Erratum]

Authors Price D, Keininger DL, Viswanad B, Gasser M, Walda S, Gutzwiller FS

Received 27 June 2018

Accepted for publication 27 June 2018

Published 25 July 2018 Volume 2018:13 Pages 2253—2254

DOI https://doi.org/10.2147/COPD.S178410


Price D, Keininger DL, Viswanad B, et al. Int J Chron Obstruct Pulmon Dis. 2018;13:695–702.

The author has advised that several changes need to be made to the paper.

Page 698, Figure 1 should be replaced.

Page 699, Results section, Left column, Second paragraph, “Of the patients who did not feel confident, more patients reported overdosing with Genuair, Ellipta, and Respimat (33.2%, 29.4%, and 21.4%, respectively).” should read “Of the patients who did not feel confident, more patients reported overdosing with Genuair, Ellipta, and Respimat (35.2%, 29.4%, and 21.4%, respectively).”

Page 700, Discussion section, Right column, Fourth para¬graph, “Limitations of the survey were that measures of patient adherence were based on patient report. Additionally, there may have been possible selection bias and recall bias. The survey was also not a randomized trial and reflected real-world experience.” should read “All possible efforts were made to ensure that the data received on Respimat were referring to tiotropium and not the use of short-acting bronchodilators; however this needs to be considered as a limitation of this analysis. Further limitations of the survey were that measures of patient adherence were based on patient report. Due to the nature of the trial, there might have been some recollection bias of some patients in spe¬cific countries, which indicated using the Respimat device longer than it had been approved. Additionally, there may have been possible selection bias and recall bias. The survey was also not a randomized trial and reflected real-world experience.”

Read the original article.
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]